|
Work in the area of genetics and genomics undertaken by the OECD Biotechnology Division includes:
OECD Guidelines for Human Biobanks and Genetic Research Databases
The OECD Working Party on Biotechnology is developing Council Guidelines on human biobanks and genetic research databases (HBGRDs) through an expert group of member countries. The Guidelines are intended to assist both OECD and non-OECD governments in the development of policies applicable to HBGRDs and to provide guidance for private and public sector HBGRDs.
OECD Guidelines on Quality Asssurance in Molecular Genetic Testing
In May 2007, OECD member countries adopted the Guidelines for Quality Assurance in Molecular Genetic Testing. The Guidelines offer Principles and Best Practices for the quality assurance of molecular genetic testing offered in a clinical context.
OECD Guidelines on Licensing of Health Care Genetics
In February 2006, OECD member countries adopted the Guidelines for the Licensing of Genetic Inventions. The Guidelines offer Principles and Best Practices for the licensing of intellectual property rights that relate to genetic inventions used for the purpose of human health care.
Pharmacogenetics
The book Pharmacogenetics: Opportunities and Challenges for Health Innovation and Care (forthcoming late 2009) will examine the challenges facing pharmacogenetics across the health innovation cycle and into the clinic, and review the impact to date of pharmacogenetics on both pharmaceutical R&D and clinical care.
Biomarkers and Targeted Therapies
Scientific advances in biotechnology are ushering in a new era of medicine: targeted therapies and personalized medicine are coming of age. Traditional medicine manages a disease through standard treatments, without taking account of existing variability between individuals or groups of population.
|
